{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:47:48Z","timestamp":1790704068987,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.ijantimicag.2009.02.003","type":"journal-article","created":{"date-parts":[[2009,4,2]],"date-time":"2009-04-02T05:29:10Z","timestamp":1238650150000},"page":"121-130","source":"Crossref","is-referenced-by-count":42,"title":["Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004\u20132007)"],"prefix":"10.1016","volume":"34","author":[{"given":"Niels","family":"N\u00f8rskov-Lauritsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Marchandin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Dowzicky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 3","key":"10.1016\/j.ijantimicag.2009.02.003_bib1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1469-0691.2008.01957.x","article-title":"Strategies for managing today's infections","volume":"14","author":"Carmeli","year":"2008","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 3","key":"10.1016\/j.ijantimicag.2009.02.003_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1469-0691.2008.01958.x","article-title":"Evolving problems with resistant pathogens","volume":"14","author":"Chastre","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2009.02.003_bib3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1517\/13543784.17.2.131","article-title":"Metallo beta lactamases in Pseudomonas aeruginosa and Acinetobacter species","volume":"17","author":"Gupta","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ijantimicag.2009.02.003_bib4","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1128\/AAC.40.9.2226","article-title":"Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection","volume":"40","author":"Bergeron","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2009.02.003_bib5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.diagmicrobio.2005.05.003","article-title":"Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000\u20132004)","volume":"52","author":"Fritsche","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2009.02.003_bib6","first-page":"1059","article-title":"Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections","volume":"3","author":"Townsend","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.ijantimicag.2009.02.003_bib7","unstructured":"Wyeth Pharmaceuticals Inc. Tygacil\u00ae product insert. Philadelphia, PA: Wyeth Pharmaceuticals Inc; 2007. http:\/\/www.wyeth.com\/hcp\/tygacil (Accessed 06.08.08)."},{"key":"10.1016\/j.ijantimicag.2009.02.003_bib8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1469-0691.2007.01943.x","article-title":"Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the Tigecycline Evaluation and Surveillance Trial","volume":"14","author":"Rodloff","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2009.02.003_bib9","unstructured":"National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 6th ed. Document M7-A6. Wayne, PA: NCCLS; 2003."},{"key":"10.1016\/j.ijantimicag.2009.02.003_bib10","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 16th ed. Document M100-S16. Wayne, PA: CLSI; 2006."},{"key":"10.1016\/j.ijantimicag.2009.02.003_bib11","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.1469-0691.2003.00591.x","article-title":"MYSTIC Study Group (Europe). The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997\u20132000","volume":"9","author":"Turner","year":"2003","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2009.02.003_bib12","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1469-0691.2004.00942.x","article-title":"ARPAC Steering Group. Antimicrobial resistance of Acinetobacter spp. in Europe","volume":"10","author":"Van Looveren","year":"2004","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2009.02.003_bib13","doi-asserted-by":"crossref","first-page":"i29","DOI":"10.1093\/jac\/dkn249","article-title":"A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae","volume":"62","author":"Vasilev","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2009.02.003_bib14","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1128\/AAC.47.10.3089-3098.2003","article-title":"In vitro susceptibilities of gram-negative bacteria isolated from hospitalized patients in four European countries, Canada, and the United States in 2000\u20132001 to expanded-spectrum cephalosporins and comparator antimicrobials: implications for therapy","volume":"47","author":"Wenzel","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2009.02.003_bib15","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1469-0691.2007.01850.x","article-title":"Prevalence and spread of extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae in Europe","volume":"14","author":"Cant\u00f3n","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2009.02.003_bib16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3201\/eid1402.070350","article-title":"Dissemination of clonally related Escherichia coli strains expressing extended-spectrum \u03b2-lactamase CTX-M-15","volume":"14","author":"Coque","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2009.02.003_bib17","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1128\/AAC.46.7.2208-2218.2002","article-title":"Diversity of \u03b2-lactam resistance-conferring amino acid substitutions in penicillin-binding protein 3 of Haemophilus influenzae","volume":"46","author":"Dabernat","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2009.02.003_bib18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/jac\/dki167","article-title":"Susceptibility of European \u03b2-lactamase-positive and -negative Haemophilus influenzae isolates from the periods 1997\/1998 and 2002\/2003","volume":"56","author":"Fluit","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2009.02.003_bib19","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1128\/AAC.00354-07","article-title":"Ampicillin-resistant non-\u03b2-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime","volume":"51","author":"Garc\u00eda-Cobos","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2009.02.003_bib20","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1128\/AAC.49.7.2834-2839.2005","article-title":"Genetic approach to study the relationship between penicillin-binding protein 3 mutations and Haemophilus influenzae \u03b2-lactam resistance by using site-directed mutagenesis and gene recombinants","volume":"49","author":"Osaki","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2009.02.003_bib21","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.3201\/eid1009.040069","article-title":"Methicillin-resistant Staphylococcus aureus in Europe, 1999\u20132002","volume":"10","author":"Tiemersma","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2009.02.003_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2334-7-29","article-title":"Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centres (2005)","volume":"7","author":"Sader","year":"2007","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2009.02.003_bib23","first-page":"124","article-title":"Vancomycin-resistant enterococcal bacteremia: comparison of clinical features and outcome between Enterococcus faecium and Enterococcus faecalis","volume":"41","author":"Chou","year":"2008","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2009.02.003_bib24","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1128\/AAC.01581-06","article-title":"Risk factors for development of multiple-class resistance to Streptococcus pneumoniae strains in Belgium over a 10-year period: antimicrobial consumption, population density, and geographic location","volume":"51","author":"Van Eldere","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2009.02.003_bib25","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1128\/AAC.49.7.2903-2913.2005","article-title":"Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003","volume":"49","author":"Reinert","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2009.02.003_bib26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1476-0711-3-14","article-title":"Emerging resistance among bacterial pathogens in the intensive care unit\u2014a European and North American Surveillance study (2000\u20132002)","volume":"3","author":"Jones","year":"2004","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.ijantimicag.2009.02.003_bib27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.diagmicrobio.2005.06.001","article-title":"Tigecycline Evaluation and Surveillance Trial (TEST Program) Group. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004)","volume":"52","author":"Hoban","year":"2005","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857909000673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857909000673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,19]],"date-time":"2019-05-19T04:05:45Z","timestamp":1558238745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857909000673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0924857909000673"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2009.02.003","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}